Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal study with no clinical in vivo human outcome data
PubMed 34085419 · doi:10.1002/advs.202100233
What was done
Researchers investigated the use of hyperbaric oxygen (HBO) to overcome physical barrier and immunosuppressive limitations of programmed cell death-1 (PD-1) antibody therapy in stroma-rich solid malignancies. The intervention was evaluated in rodent solid tumor models and ex vivo cancer cells from patients with hepatocellular carcinoma, assessing extracellular matrix degradation, hypoxia reversal, antibody delivery, and cytotoxic T-cell infiltration.
What was found
The abstract reports no numerical values, exact effect sizes, or statistical metrics. It describes qualitative findings: HBO reduced main extracellular matrix components (collagen and fibronectin), facilitated PD-1 antibody delivery and T-cell penetration into tumor parenchyma, disrupted hypoxia-mediated immunosuppression, and triggered cytotoxic T lymphocytes and immunological memory that inhibited tumor relapse in rodent models and patient-derived hepatocellular carcinoma cells.
Why it matters
Dense stroma and hypoxia frequently limit the clinical efficacy of immune checkpoint blockade in solid tumors. This paper proposes a biophysical adjuvant approach—using hyperbaric oxygen to remodel the tumor microenvironment and enhance antibody delivery.
Limits
The study is entirely preclinical, relying on rodent models and in vitro/ex vivo human cells, so clinical efficacy and safety in humans remain unknown. The abstract provides no quantitative data, sample sizes, exact hyperbaric oxygen treatment regimens, or adverse effect profiles.
Cited by
- supports Hyperoxygenation enhances T-cell metabolism and infiltration, reduces PD-L1 expression, and improves the efficacy of immune checkpoint inhibitor therapy.